Since April 2024, Berlin has cemented its place as the spiritual centre of the European cannabis industry. It is home not only to the policymakers, institutions, and business leaders that have shaped the German market, but also to the conversations that will illuminate where it is heading.
On 10 June, the European Cannabis Insights Summit brought over 100 of those voices together at Palisa.de in Friedrichshain for a half-day of data-driven presentations and in-depth discussion.
Produced by Business of Cannabis in partnership with Prohibition Partners, the day’s diverse discussions made clear that two years on, the market has outgrown the narratives which continue to be used to describe it.
The feared recreational flood following April 2024’s reclassification never materialised, with data presented by Bloomwell showing new patients are condition-led, not lifestyle-led. Beneath the headlines, the commercial picture has grown far more nuanced and, crucially, much harder to read and predict.
Wholesale margins are running at approximately half of what operators modelled at entry. The statutory insurance channel, where revenue per patient is roughly 10 times that of the private pay equivalent, is being suppressed by physician fear of financial liability rather than lack of demand.
With a single policy outcome, on telemedicine, GKV reimbursement, or adult-use pilots, capable of shifting annual market value by more than €300 million, decisions are being made in an information environment that public import data alone can no longer adequately describe.
Analysis of Patient Behaviour Following German Cannabis Reclassification
Dr Julian Wichmann, Co-Founder & CEO, Bloomwell (Presenter) | Julian Vaterrodt, CBO, Cannaleo Digital | Alfredo Pascual, Head of Strategy & Development, Cannamedical (Moderator)
Bloomwell‘s live patient database, spanning 2022 to the present, provided some of the summit’s most closely watched data, and several findings that ran counter to political expectations.
- The feared post-reclassification flood of recreational users gaming the medical channel has not materialised. New entrants are genuine first-time medical cannabis patients, not illicit-to-medical migrants.
- Consultation costs on Bloomwell’s platform have fallen from as high as €2,000 per month before April 2024 to zero, removing a structural access barrier for lower-income patients with genuine medical need.
- Median prescription volume has not shifted materially since reclassification, directly countering political claims of reckless over-prescribing.
- The most significant structural change is prescription frequency. Repeat intervals have shortened from roughly 30 days to approximately 14, meaning cannabis telemedicine now involves more frequent physician contact than conventional GP care, where follow-up appointments average 90 days.
- East Germany is now the fastest-growing region for new patient onboarding. Under the previous in-person model, sparse specialist coverage made access prohibitive across much of the former East; telemedicine has eliminated that geography barrier entirely.
- The next wave of patients will be older and more female — a cohort with different product needs, and one the current high-THC flower-dominant market is poorly positioned to serve.
Mapping What Comes Next: Scenarios for Europe’s Priority Cannabis Markets
Alex Khourdaji, Senior Analyst, Prohibition Partners (Moderator) | Alfredo Pascual, Head of Strategy & Development, Cannamedical | Stephen Murphy, Co-Founder, Prohibition Partners
Prohibition Partners presented its move from single-figure market estimates to scenario-based modelling, using Poland as a live stress test for European assumptions.
- Poland’s November 2024 telemedicine ban caused a 57% volume decline. By December 2025, volumes had recovered to 608 kilograms dispensed in a single month — the highest ever recorded — demonstrating that demand is structural. Access restrictions are a shock; they are not demand destruction.
- Recovery was driven by hybrid mobile clinics operating a few hours per week in rural towns, a workaround that regulators did not close off and a model with direct relevance for Germany.
- Germany’s telemedicine restriction bill is assessed as having a very low probability: it has stalled in the Bundestag, lacks coalition support, and faces enforcement barriers under EU Directive 2001/11. Modelled against Polish decline rates, an equivalent restriction would represent roughly a 40% market value contraction.
- GACP wholesale pricing has fallen from €2.00 per gram to approximately €1.16, with Canada accounting for up to 75% of European supply when redistribution via Portugal is included.
- France is the most significant medium-term opportunity: commercial sales expected from 2027, a reimbursement framework partially in place (65% for severe conditions), and a first-mover supply chain advantage available now for operators willing to build ANSM relationships ahead of launch.
- The UK is projected to grow 4x over the next four to five years, with its private self-pay model insulating pricing from the compression Germany is experiencing.
READ MORE…
Pilot to Policy: What Europe’s Cannabis Trials Are Teaching Us
Finn Age Hänsel, Co-Founder & CEO, Sanity Group | Philipp Hagenbach, Co-CEO, CANNAVIGIA | Olivia Ewenike, Lawyer, Ewenike
Switzerland’s cannabis pilots, now running for two and a half years across eight cantons, provided the session’s most compelling regulatory evidence.
- Data privacy is the primary participation barrier in both markets. Switzerland’s solution, routing demographic data through an independent research institute, with the government receiving aggregate statistics only, has proven effective, and any German pilot must resolve the same question before it can achieve meaningful scale.
- Across all Swiss pilot projects, 66% of registered participants report they no longer buy cannabis from illegal channels. In the Basel-Landschaft canton, the most developed pilot with 1,800 participants representing roughly 3% of the local adult population, half have halved the frequency of their illicit purchases.
- Participants are measurably shifting toward less harmful consumption methods when harm reduction is explained at point of sale, a public health function the dispensary model delivers that mail-order and telemedicine cannot.
- Consumer pilot projects will not launch in Germany in the current legislative period. Federal Drug Commissioner Professor Streeck has indicated public support, with parameters of participants aged 25 and above and a maximum of 5 grams per person, but the political conditions are not in place.
- The recommended design for any future German pilot is a mixed model: licensed dispensaries in urban areas combined with telemedicine and delivery in rural areas. A dispensary-only approach would not work given Germany’s geographic diversity.
Who Is the Modern Cannabis Patient? Reimbursement, Demographics and the Real Profiles Behind the Data
Garvin Hirt, CEO, Copeia (Presenter) | Lisa Haag, Director, BvCW (Moderator) | Christoph Viebig, COO, CKM Group / Green Medical
Real-world evidence data from hundreds of physician-submitted case files painted a picture of two structurally distinct German patient populations, and a market largely focused on the less valuable of the two.
- The GKV statutory insurance channel serves patients aged 56 to 65 on average, 61% female, therapy-resistant and often opioid-dependent, prescribed balanced extracts at a fixed reimbursement rate of €19.28 per gram. The private pay telemedicine channel serves a predominantly male cohort averaging around 30 years old, paying €6 to €7 per gram for high-THC flower. GKV patients consume 3.5 times the volume; revenue per patient is approximately 10 times that of a private pay equivalent.
- The primary barrier to GKV prescribing is not clinical uncertainty; it is the physician’s fear of financial clawback. Documented penalties exceeding €10,000, where physicians were held personally liable for therapy costs the insurer judged unjustified, have been sufficient to deter broad prescribing.
- No pharma-style sales force is educating German physicians on which patients would benefit from cannabis therapy. One physician, whose anonymised case data was presented at the session, described the gap plainly: ‘Nobody ever visited me. Nobody explained which patients would benefit.’
- Among 405 patients in the PACT evidence platform dataset, cannabis therapy was associated with a measurable reduction in total medications used. Half the cohort were on opioids at the start of treatment; a significant proportion achieved reduction or full discontinuation.
- Germany’s first domestically produced, fully licensed cannabinoid-based medicine is expected to reach market by end of summer 2026, indicated for chronic back pain affecting 1.5 to 2 million patients, and enabling on-label prescribing for the first time. The panel’s view: mainstream acceptance of cannabinoids as a drug class benefits the whole sector.
Supply Under Pressure: Imports, Exports and the Realities of European Trade
Moritz Forster, Founder & CEO, MJ Content & Communications (Moderator) | Boris Moshkovits, Co-Founder & Managing Director, alephSana
European supply chains are shifting rapidly, and this panel took an honest look at the economics and how unsustainable the present structure has become.
- The market grew 400% in the months following Germany’s April 2024 reclassification. Most operators were not structurally ready. Calculated margins of 30% are being realised closer to 15% across the entire value chain. ‘I could sell more if I could buy more, but to buy more I need to plan more, and for that I need more cash,’ one panellist summarised the bind.
- At a retail pharmacy price of €5 per gram, no participant in the value chain makes meaningful returns. Pharmacies retain 20 to 23%; distributors buy at roughly €3 per gram and sell at roughly €4; GACP producers sell at €2.50 to €3.00, barely covering costs.
- Canada’s oversupply is structural, not temporary. Its domestic recreational market is contracting, releasing surplus GACP product into European distribution at prices that cannot support a quality medical supply chain, and it now accounts for an estimated 75% of European supply when redistribution via Portugal is included.
- The session’s sharpest exchange concerned GACP versus EU GMP. The two are not equivalent — GACP covers cultivation; EU GMP covers the full manufacturing, testing, and quality management process — yet the market treats them as interchangeable. A practice described as ‘GMP washing’ has emerged: product passes through a GMP facility for minimal processing to acquire the label without undergoing pharmaceutical-grade manufacturing. If regulators mandate a transition to EU GMP only, panellists estimated 80% of current European supply would disappear overnight.
- The industry is making a category error by conflating medical patients and recreational consumers. Medical patients need efficacy, consistency and reliability; they will pay a premium and stay loyal once a product works. Recreational consumers switch on price. Confusing the two, panellists argued, is what drives the race to the bottom.
- The UK received the session’s most positive assessment of any non-German market: profitable, price-resilient through its self-pay model, and characterised by patient loyalty built through clinic relationships. Consistent, reliable products are outperforming novelty.
